Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

October 12, 2024 07:57 PM AEDT | By Cision

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform — Image source: Kalkine Media

Recent News

The GMIF2024 Annual Awards Revealed: Micron, Silicon Motion, Western D...

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement...

The Rise of CBD in Cambodia Dara Sakor Tourism, Infrastructure and Inv...

Shanghai Electric Showcases Green Energy Innovations at Enlit Asia 202...

CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. Under the agreement, Ailux Biologics grants Janssen and its affiliates a non-exclusive license to leverage its XtalFold™ platform for the discovery and engineering of biologics. XtalFold™ is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases. The agreement was facilitated by Johnson & Johnson Innovation.

XtalFold™ utilizes sequence information alone to model the interaction between biomolecules, which forms the foundation of biotherapeutics like monoclonal antibodies. In rigorous benchmark studies, XtalFold™ achieved state-of-the-art performance in terms of overall success rate and the quality of hard-to-model regions like the antibody-antigen interface. Since its launch one year ago, XtalFold™ has been fully validated in more than 30 partner and internal programs, delivering highly impactful results in a variety of use cases, including antigen design, epitope identification, affinity maturation, pH-sensitivity engineering, and bispecifics design.

Yi (Alex) Li, VP of XtalPi and Head of Ailux Biologics, said: "Biologics are intricate machines that operate in three-dimensional space. XtalFold™ enables the visualization and design of biologics in 3D space in real time, which could take months using currently available experimental approaches. We are excited to share with Janssen this foundational technology, which has already proven transformative in-house."

About XtalPi
XtalPi ("QuantumPharm Inc.", stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three postdoctoral physicists at Massachusetts Institute of Technology (MIT), the company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.

About Ailux Biologics
Ailux Biologics is a division of XtalPi dedicated to the innovation in large molecule drug discovery. With a team of around 100 experts, Ailux has established a state-of-the-art biologics discovery lab, a proprietary database purpose-built for AI (AtlaX™) and a trio of AI platforms, including a structure modeling suite (XtalFold™), a generative large language model for proteins (XenProT™) and a predictive AI suite for biologics (Xentient™). Ailux partners with pharma and biotech companies to accelerate their biologics programs with AI-powered, lab-validated solutions. To learn more, visit https://ailuxbio.com/ and follow @Ailux Biologics on Linkedin.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.